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Mass spectrometry has emerged as a leading tool in the field of chemistry as an 
analytical method for the characterization of small molecules, proteins, and other 
complex biomolecules. Specifically, cyclic and stapled peptides have become an 
intriguing class of biomolecules in drug research afforded to them because of their 
biological stability and resistance to proteolytic digestions. However, challenges are 
presented in regards to the characterization of these molecules as traditional methods are 
ineffective in determining a ring-opening site on the peptidic backbone. Additionally, 
lipid A, the hydrophobic domain of lipopolysaccharide (LPS), consists of a 
diglucosamine backbone and is responsible for fastening LPS to a membrane surface. 
Lipid A becomes a biologically relevant molecule to study as its function within LPS is 
directly related to the infectious and toxic properties of gram-negative bacteria, but the 
molecule is structurally complex and offers many challenges in terms of traditional mass 
spectrometry characterization. Presented in the thesis are methods to further comprehend 
 vi 
structural motifs related to the aforementioned biomolecules. The “ornithine effect”, 
which describes the conversion of an arginine residue to an ornithine residue via reaction 
with hydrazine and subsequent preferential cyclization via nucleophilic attack of the 
ornithine side-chain to the neighboring carbonyl group, inducing heterolytic cleavage of 
the adjacent amide bond under gentle activation, is used to preferentially open cyclic and 
stapled rings to linearize these challenging biomolecules. Ramped collisional and photon 
based activation (in terms of energy and laser pulses) of lipid A molecules that contain 
differences in acyl-chain length and connectivity reveal general trends about the lability 
of certain bonds on the lipid A molecules themselves and paints a picture of the overall 
fragmentation trends associated with variations in lipid A structural motifs.  
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Scheme 1.1. Conversion of an arginine residue into an ornithine residue results in a 
mass shift of 42 Da and proceeds in the presence of hydrazine. Upon gas 
phase activation, the ornithine residue cyclizes via nucleophilic attack 
and the adjacent amide bond is heterolytically cleaved.  This figure is 





Chapter One: Exploitation of the Ornithine Effect Enhances 
Characterization of Stapled and Cyclic Peptides1 
OUTLINE 1.1 
A method to facilitate the characterization of stapled or cyclic peptides is reported 
via an arginine-selective derivatization strategy coupled with MS/MS analysis. Arginine 
residues are converted to ornithine residues through a deguanidination reaction that 
installs a highly selectively cleavable site in peptides. Upon activation by CID or UVPD, 
the ornithine residue cyclizes to promote cleavage of the adjacent amide bond. This Arg-
specific process offers a unique strategy for site-selective ring opening of stapled and 
cyclic peptides. Upon activation of each derivatized peptide, site-specific backbone 
cleavage at the ornithine residue results in two complementary products: the lactam ring-
containing portion of the peptide and the aminecontaining portion. The deguanidination 
process not only provides a specific marker site that initiates fragmentation of the peptide 
but also offers a means to unlock the staple and differentiate isobaric stapled peptides. 
INTRODUCTION 1.2 
Cyclic, stapled, and branched peptides constitute a unique and growing class of 
biomolecules with promise as therapeutics because of their biostability and resistance to 
proteolytic digestion in physiological environments [1–7]. In the context of therapeutics, 
peptide-based drug candidates display both advantages and disadvantages in comparison 
to their small molecule counterparts. Peptides, while frequently less toxic than small 
                                                 
1 Crittenden, C.M., Parker, W.R., Jenner, Z.B., Bruns, K.A., Akin, L.D., McGee, W.M., Ciccimaro, E., 
Brodbelt, J.S.: Exploitation of the Ornithine Effect Enhances Characterization of Stapled and Cyclic 
Peptides. J. Am. Soc. Mass Spectrom. (2016) 27:856-863.  Research funding provided by the NSF and the 
Welch Foundation. CMC’s contributions: experimental design, execution, and analysis. 
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molecules when administered intravenously and exhibiting higher selectivity for specific 
biological functions, do not traverse cell membranes with the ease that small molecules 
do and are prone to proteolytic degradation [8, 9]. However, peptides that are protected 
from degradation via cyclization or stapling have been shown to exhibit high potency and 
low toxicity, resulting in more promising candidates for drug administration than their 
linear counterparts [3–7]. A myriad of nonlinear peptides are found naturally in plants, 
fungi, and bacteria as well as synthetic ones produced in the laboratory [10–18]. 
Valinomycin, for example, is a cyclic dodecadepsipeptide produced by Streptomyces 
fulvissimus with potent antibacterial properties while also acting as a potassium-selective 
ionophore [19, 20]. Enzyme inhibition is another pharmaceutical application that is 
associated with cyclic peptides, as shown by two examples of the Bowman-Birk class of 
protease inhibitors, Sunflower trypsin inhibitor-1 (SFTI-1) and Momordica 
cochinchinensis trypsin inhibitor-II (MCoTI-II) [21].  
From an analytical standpoint, structural characterization of cyclic or stapled 
peptides is significantly more challenging than elucidation of linear peptides. The success 
of tandem mass spectrometry for sequencing peptides is based on production of 
predictable N-terminus and C-terminus fragment ions via cleavage of the peptide 
backbone. Cyclic peptides require cleavage of two backbone bonds to generate fragment 
ions, and the lack of natural N-terminal and C-terminal positions confounds an orderly 
mapping of the sequence of residues. Stapled peptides suffer from a similar pitfall in the 
region of the peptide containing the stapled (cyclized) portion and also typically contain 
hydrocarbon (non-peptide-like) linkers that constitute the staple. Several mass 
 3 
spectrometric techniques, including collision induced dissociation (CID) [20–25], MS
n
 
methods [23, 25–27], electron capture dissociation (ECD) [28], and complexation 
strategies [29, 30], have emerged as the most valuable tools to assist in the 
characterization of the sequences of non-linear peptides.  
In addition to the use of MS
n
 methods to facilitate the characterization of cyclic 
and stapled peptides, another synergistic strategy evolves from site-selective 
fragmentation processes that may be used to “anchor” a particular location in a molecule 
based on a site-specific cleavage. Once an anchor point is established, all other 
fragmentation pathways and the resulting product ions can be referenced to the anchor 
point. Highly selective or preferential bond-specific cleavages remain relatively rare 
occurrences upon activation of peptides and proteins. As one example, the proline effect 
is one of the few well-established site-specific cleavage upon activation, occurring N-
terminal to proline residues due to the increased basicity of the N-alkylated amide bond 
as well as the increased steric hindrance about the residue [31, 32]. The proline directed 
cleavage creates a readily recognized fragment ion in the MS/MS spectra of peptides. 
Along these lines, there has been renewed interest in the development of peptide 
derivatization strategies to install tags with labile bonds or ones with selectively cleavable 
groups in order to promote bond-selective cleavages [33–39]. Recently, the “ornithine 
effect” has been reported as a site-specific cleavage occurring C-terminal to ornithine 
residues [40, 41]. Upon collisional activation of an ornithine-containing peptide, the 
amine of the ornithine residue cyclizes via nucleophilic attack at the adjacent carbonyl 
group, resulting in a characteristic and preferential cleavage C-terminal to the carbonyl 
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group. This phenomenon has been observed before, as lysine and many of its homologues 
have exhibited similar characteristics as a nucleophile previously [42–45].  
The present study explores the utility of the ornithine effect to enhance the 
characterization of cyclic and stapled peptides. By exploiting the predictability of the 
ornithine effect, unique ions are generated that allow the differentiation of isomers. Both 
collision-based and photon-based activation methods are used to characterize the 
modified and unmodified peptides. The fragment ions were assigned using an in-house 
algorithm designed to systematically generate a list of every possible combination of 
bond cleavages (including cross-ring cleavages) and the associated masses of the 
fragments. 
EXPERIMENTAL 1.3 
Materials and Reagents 
HPLC grade water and methanol used for sample preparation and dilution were 
purchased from EMD Millipore (Billerica, MA, USA) and formic acid was purchased 
from Fisher Scientific (Fairlawn, NJ, USA). Sunflower trypsin inhibitor-1 (SFTI- 1) was 
provided by Bristol-Myers Squibb (Princeton, NJ, USA). Dithiothreitol (DTT) and 
iodoacetamide (IAM) used for reduction and alkylation of disulfide bonds were 
purchased from Sigma Aldrich (St. Louis, MO, USA). Proteomics-grade trypsin was 
obtained from Promega (Madison, WI, USA). 
Synthesis and Purification of Stapled Peptides 
Stapled peptides were produced by BioSynthesis (Lewisville, TX, USA) using 
Fmoc solid phase peptide synthesis. Peptides were stapled by ring-closing metathesis 
 5 
using Grubbs’ First Generation Catalyst, and purified by preparative C18 reversedphase 
HPLC. The purity of the peptides was confirmed as >95% by analytical HPLC and by 
MALDI-TOF MS. 
Sample Preparation  
Unmodified samples were diluted to 5 uM with an equal mixture of methanol and 
water with 1% formic acid prior to direct infusion ESI. Stapled peptides and SFTI-1 were 
mixed with excess hydrazine hydrate for 4 h at 55 °C in water to promote the conversion 
of arginine to ornithine. The reaction mixture was dried under vacuum (Thermo Savant 
DNA 120 Speedvac Concentrator, San Jose, CA, USA) to remove organics and diluted to 
5 uM with an equal mixture of methanol and water with 1% formic acid prior to direct 
infusion ESI. After the incubation of SFTI-1 with hydrazine hydrate, the intramolecular 
disulfide bond was reduced with dithiothreitol (100 mM in water) for 45 min at 55 °C 
and alkylated with iodoacetamide (100 mM in water) for 45 min protected from light at 
room temperature. 
Mass Spectrometry and Photodissociation 
All MS experiments were performed on a Thermo Scientific Orbitrap Elite mass 
spectrometer (San Jose, CA, USA) custom fit with an unfocused, non-collimated 
Coherent ExciStar 193 nm excimer laser (Santa Clara, CA, USA) to perform ultraviolet 
photodissociation, as previously described [46, 47]. Peptides, both modified and 
unmodified, were analyzed by direct infusion electrospray ionization with a spray voltage 
of 4 kV and a capillary temperature of 275 °C. For all CID experiments, the normalized 
collision energy (NCE) was varied to reduce the precursor to approximately 10%– 15% 
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relative abundance during an activation period of 10 ms (this is sufficient to provide rich 
fragmentation without excessive ejection of the precursor ion during resonance 
excitation). For all UVPD experiments, a laser power of 1.5–2.5 mJ/pulse and one to 
three 5-ns pulses were used. The resulting MS/MS spectra were interpreted manually as 
well as by using a custom fragment ion prediction algorithm that was developed in-house. 
Development of a Custom Algorithm for Assignment of Fragment Ions 
Several algorithms have recently been developed to assist with the 
characterization of cyclic peptides. Two of the most recent algorithms are CYCLONE 
and CycloBranch, which were developed to characterize cyclic peptides via a de novo 
strategy [48, 49]. An in-house algorithm was developed in C# to assign fragment ions of 
cyclic peptides based on interpretation of 193 nm UVPD mass spectra. Unlike 
CYCLONE and CycloBranch, this algorithm utilizes a naïve approach that calculates all 
potential fragment ions which may arise from the cleavage of any bond in the peptide’s 
structure and cross-ring cleavages based on candidate structures. Moreover, the custom 
algorithm accepts any type of candidate structure, including stapled peptides containing 
unnatural amino acids, unlike other available algorithms. The structures of the candidate 
peptides were generated in ChemDraw Perkin Elmer (Waltham, MA, USA). The 
structures were assigned atom numbers and implicit hydrogens were selected to be 
hidden. The final structure was saved as a cdxml file. The XML from the cdxml files 
were then parsed by the algorithm and converted into an undirected graph (abstract data 
structure). A naïve approach was employed in which fragments were calculated through 
the systematic removal of each edge in the graph from the candidate molecule’s structure. 
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Additionally, with a ring size specified, fragments resulting from cross ring cleavages 
could also be calculated (resulting from the cleavage of two bonds). These calculated 
fragment ions were saved in a SQLite database [50], which could be exported into an 
Excel file. The ions in the MS/MS spectra were then manually compared with the 
theoretically calculated masses. 
RESULTS AND DISCUSSION 1.4 
Conversion of arginine to ornithine by deguanidination in the presence of 
hydrazine causes a mass shift of 42 Da, as shown in Scheme 1.1. Subsequent activation 
of an ornithine-containing peptide may result in cyclization via nucleophilic attack of the 
side-chain amine of the ornithine residue on a neighboring carbonyl carbon, causing a 
heterolytic cleavage of the adjacent amide bond. This process is referred to as the 
“ornithine effect,” and, in short, is based on a decrease in proton affinity in the gas phase 
when an arginine residue is converted to an ornithine residue (see reference [40] for a 
complete explanation of the ornithine effect and see reference [42], which reports the gas-
phase proton affinity of ornithine). This site-specific cleavage affords a facile, predictable 
fragmentation pathway for arginine-containing peptides and offers a convenient way to 
convert cyclic peptides into acyclic ones. In this study, both CID and UVPD are 
implemented to induce the ornithine effect as a means to simplify the characterization of 
stapled and cyclic peptides.  
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Scheme 1.1. Conversion of an arginine residue into an ornithine residue results in a mass 
shift of 42 Da and proceeds in the presence of hydrazine. Upon gas phase 
activation, the ornithine residue cyclizes via nucleophilic attack and the 




Figure 1.1. Structure of the stapled peptide, (a) [H2N]-HG-X-ARA-X-GAD-[CO2H] (Mr 
= 1004.12 Da)  and (b) [H2N]-HG-X-RAA-X-GAD-[CO2H] (Mr = 1004.12 
Da). The stapled pentenyl alanines are located between atom numbers 10 
and 36. The “X” represents pentenyl alanine residues that have been stapled 
together through ruthenium catalyzed ring-closure metathesis. 
When analyzing the MS/MS spectra of stapled and cyclic peptides, there is an 
inherent challenge in nomenclature associated with the fragment ions due to the presence 
of multiple branches or the lack of any terminal positions. In this study, an in-house 
algorithm was developed to assist in the identification and assignment of the resulting 
fragment ions. For the stapled and cyclic peptides, a fragment ion involving the cyclic 
portion can only be produced via cleavages of two bonds (one in the cyclic region and 
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one in the linear segment, typically creating an internal ion) or via a cross-ring cleavage. 
A single bond cleavage between atom numbers 1 and 2 is annotated as “[atom number 1 | 
atom number 2]” and the cleavage of two bonds between atom numbers 1 and 2 and atom 
numbers 3 and 4 simultaneously is annotated as “[atom number 1 | atom number 2 || atom 
number 3 | atom number 4]”. If multiple cleavages lead to the same m/z ratio, all possible 
fragments are listed. 
 










H]. An asterisk (*) represents presence of the modification from 
arginine to ornithine. The “X” represents pentenyl alanine residues that have 
been stapled together through ruthenium catalyzed ring-closure metathesis. 
Two variants of a stapled peptide with sequences [H2N]- HG-X-ARA-X-GAD-
[CO2H] and [H2N]-HG-X-RAA-XGAD-[CO2H] (Figure 1.1) were characterized. The 
“X” represents pentenyl alanine residues that have been stapled together through 
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ruthenium-catalyzed ring-closure metathesis.The ESI mass spectra of one of the 
unmodified and ornithine-modified stapled peptides (Figure 1.2) show that the 
conversion of the stapled peptide to the ornithine-containing analogue was an efficient 
reaction. As demonstrated in Figure 1.3, the CID mass spectra of the two unmodified 
stapled peptides are nearly identical, resulting in no fragment ions that are unique to 
either of the two isomeric peptides (fragmentation maps for the unmodified stapled 
peptides are shown in Figure 1.4).  
 










H]. The “X” represents pentenyl alanine residues that have been 
stapled together through ruthenium catalyzed ring-closure metathesis. 
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Figure 1.4. Fragmentation maps obtained using CID (240K resolution) of unmodified 









H]. The “X” represents pentenyl alanine residues that 
have been stapled together through ruthenium catalyzed ring-closure 
metathesis. Unique fragment ions detected for the ornithine-containing 
peptides are indicated in red. 
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H]. The “X” represents pentenyl alanine residues that have been 
stapled together through ruthenium catalyzed ring-closure metathesis. Red 
labels designate the unique fragment ions between the isobaric stapled 
peptides (regions around the fragments identified as [57|58] and [53|54] 
have been magnified 5x for clarity). See expanded regions of the spectra in 
Figure 1.4 and Figure 1.6 showing the differences in fragment ions between 
the two ornithine-containing stapled peptides. 
However, after conversion of the Arg residues to ornithine groups, unique 
fragments are identified for each (Figure 1.5). Cleavages between atoms numbered 57 
and 58 (annotated as [57|58]) and 12 and 19 ([12|19]) for [H2N]-HG-X-AOA-XGAD-
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[CO2H] and cleavages between atoms numbered 53 and 54 ([53|54]) and atoms numbered 
28 and 31 ([28|31]) for [H2N]-HG-X-OAA-X-GAD-[CO2H] are observed. Expanded 
regions of these key parts of the spectra are shown in Figure 1.6 and Figure 1.7. 
Fragmentation maps for each of the two modified stapled peptides are shown in Figure 
1.8. The two unmodified isomeric peptides have no unique fragment ions in the MS/MS 
spectra, making the identification of location of the arginine residue within the stapled 
region impossible. However, as shown in Figure 1.8a and Figure 1.8b, there is clear 
indication that the ring opening and lactam formation arising from the ornithine effect 
lead to generation of unique product ions upon MS/MS.  
 










H] highlighting some of the major differences between the spectra of 
the ornithine-modified isomers. The “X” represents pentenyl alanine 














H] highlighting some of the major differences between the two spectra. 
The “X” represents pentenyl alanine residues that have been stapled together 
through ruthenium catalyzed ring-closure metathesis. 
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Figure 1.8. Fragmentation maps obtained using CID (240K resolution) of ornithine-









H]. The “X” represents pentenyl alanine 
residues that have been stapled together through ruthenium catalyzed ring-
closure metathesis. Unique fragment ions detected for the ornithine-





The unique ions of particular interest evolve from cleavages [12|19] and [57|58] 
for [H2N]-HG-X-AOA-XGAD-[CO2H], and [28|31] and [53|54] for [H2N]-HG-XOAA-
X-GAD-[CO2H]. In addition to the CID spectra detailed here, the UVPD mass spectra 
and associated fragmentation maps are shown in Figure 1.9 and Figure 1.10. A few 
additional unique fragment ions are produced by UVPD of the ornithine-modified 
peptides relative to the unmodified peptides. As another approach, stapled peptides 
containing proteolytically recognized residues, such as Arg or Lys, can be subjected to 
proteolysis to cleave the cyclic stapled segment. The products generated upon tryptic 
digestion of the two stapled peptides are shown in Figure 1.11, Figure 1.12, and Figure 
1.13. Tryptic digestion can result in more complex mixtures if multiple arginine and 








Figure 1.9. UVPD mass spectra (2.5 mJ, 3 pulses, 240K resolution) of arginine- and 


















H].  The “X” 
represents pentenyl alanine residues that have been stapled together through 
ruthenium catalyzed ring-closure metathesis. Red labels designate the 
unique fragment ions between the isobaric stapled peptides. 
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Figure 1.10. Fragmentation maps obtained using UVPD (2.5 mJ, 3 pulses, 240K 



















H]. The “X” represents pentenyl alanine residues that have been 
stapled together through ruthenium catalyzed ring-closure metathesis. 
Unique fragment ions detected for the ornithine-containing peptides are 




Figure 1.11. ESI mass spectrum of (a) unmodified stapled peptide [H2N]-HG-X-ARA-
X-GAD-[CO2H] and (b) unmodified stapled peptide [H2N]-HG-X-RAA-X-
GAD-[CO2H], both following trypsin digestion. An asterisk (*) represents 
presence of the tryptic product of the stapled peptides. The “X” represents 
pentenyl alanine residues that have been stapled together through ruthenium 




Figure 1.12. CID mass spectra (240K resolution) of 2+ unmodified stapled peptides after 
trypsin digestion. (a) [H2N]-HG-X-ARA-X-GAD-[CO2H]. (b) [H2N]-HG-
X-RAA-X-GAD-[CO2H]. The “X” represents pentenyl alanine residues that 
have been stapled together through ruthenium catalyzed ring-closure 
metathesis. Red labels designate the unique fragment ions between the 




Figure 1.13. UVPD (2.5 mJ, 1 pulse) mass spectra (240K resolution) of 2+ unmodified 
stapled peptides after trypsin digestion. (a) [H2N]-HG-X-ARA-X-GAD-
[CO2H]. (b) [H2N]-HG-X-RAA-X-GAD-[CO2H]. The “X” represents 
pentenyl alanine residues that have been stapled together through ruthenium 
catalyzed ring-closure metathesis. Red labels designate the unique fragment 
ions between the isobaric stapled peptides. 
Sunflower trypsin inhibitor-1 (SFTI-1) is another prime candidate to evaluate the 
utility of the ornithine effect for improving the characterization of cyclic peptides. 
Similar to the hurdle with analysis of stapled peptides, two bond cleavages are required to 
generate diagnostic fragment ions for cyclic peptides like SFTI-1. The use of the custom 
algorithm to assign m/z values for all possible cross-ring cleavage products is vital for 
predicting and assigning fragment ions for SFTI-1. SFTI-1 has a single arginine residue 
within its cyclic structure, which, upon conversion to an ornithine group and activation in 
the gas phase, causes a ring opening event that exposes a significant portion of the 
molecule (Figure 1.14).  
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Figure 1.14. Sunflower Trypsin Inhibitor-1 (SFTI-1) may undergo a ring-opening event 
when the arginine residue is converted to ornithine followed by subsequent 
collision or photon-based activation. The ring can further be manipulated by 
reducing and alkylating the disulfide bond, allowing improved sequence 
coverage of the peptide backbone. 
The arginine residue converts readily to an ornithine residue in the presence of 
hydrazine hydrate, as shown in the ESI mass spectrum (Figure 1.15). Furthermore, 
reduction and alkylation of the disulfide bond constraining the cyclic portion of the 
molecule was performed, allowing more extensive sequence coverage of the biomolecule. 
Upon CID (Figure 1.16) and UVPD (Figure 1.17), the greatest number of diagnostic 
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ions are produced and identified for the ornithine-modified peptide after reduction and 
alkylation (Figure 1.16b and Figure 1.17b). A complete list of the identified fragments 
and the associated m/z values are provided in Table 1.1, and the most prominent ones for 
the ornithinemodified SFTI-1 after reduction and alkylation are shown in Figure 1.18.  
 
Figure 1.15. ESI mass spectra of (a) unmodified cyclic peptide SFTI-1, (b) ornithine-
modified cyclic peptide SFTI-1, and (c) ornithine-modified cyclic peptide 
SFTI-1 after reduction and alkylation. An asterisk (*) represents presence of 
the modification from arginine to ornithine and a pound symbol (#) 
represents reduction and alkylation of a disulfide bond. 
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Figure 1.16. CID mass spectra (240K resolution) of doubly charged (a) reduced and 
alkylated unmodified SFTI-1 (1629.90 Da) and (b) reduced and alkylated 
ornithine-modified SFTI-1 (1587.86 Da). (NCE = 24) An asterisk (*) 
represents presence of the modification from arginine to ornithine and a 
pound (#) represents reduction and alkylation of the disulfide bond. 
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Figure 1.17. UVPD mass spectra (2.5 mJ, 1 pulse, 240K resolution) of doubly charged 
(a) reduced and alkylated unmodified SFTI-1 (1629.90 Da) and (b) reduced 
and alkylated ornithine-modified SFTI-1 (1587.86 Da). An asterisk (*) 
represents presence of the modification from arginine to ornithine and a 
pound (#) represents reduction and alkylation of the disulfide bond. 
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Figure 1.18. Fragmentation map of ornithine-modified SFTI-1 that has been reduced and 
alkylated. Red cleavages correspond to those fragment ions unique to CID; 
blue cleavages correspond to fragment ions unique to UVPD; green 
cleavages correspond to fragment ions produced by CID and UVPD. 
Additionally, CID and UVPD of unmodified SFTI-1 and ornithine-modified 
SFTI-1 without reduction and alkylation were performed and the resulting spectra are 
shown in Figure 1.19 and Figure 1.20, respectively. For comparison, a fragmentation 
map similar to Figure 1.18 is provided for the unmodified SFTI-1 (i.e., reduced and 
alkylated, but without the ornithine modification) in Figure 1.21. Although there were 
still a number of fragment ions identified for unmodified SFTI-1 (reduced and alkylated 
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but without the ornithine modification), the ambiguity associated with the cyclic nature of 
the peptide impeded the assignment of product ions. In essence, several of the fragment 
ions may arise from multiple fragmentation points across the cyclic peptide, hence 
leading to the redundancies in Table 1.1. Owing to this ambiguity, exploiting the 
ornithine effect in tandem with reduction and alkylation leads to more confident 
characterization of the peptide.  
As an alternative to the ornithinylation approach, tryptic proteolysis of SFTI-1 
was undertaken. Tryptic digestion of SFTI-1, either with reduction/alkylation or without, 
failed to cause ring opening. Because SFTI-1 is a known trypsin inhibitor [51, 52], this 
result was not surprising and emphasizes the need for alternative approaches to facilitate 










Table 1.1. Summary of fragment ions tabulated based on m/z ratios and bond cleavages 
for reduced and alkylated SFTI-1 (1629.90 Da, 2+ precursor selected) and ornithine-
modified SFTI-1 that has been reduced and alkylated (1587.86 Da, 2+ precursor 
selected). In the instances when a single m/z value has multiple fragments listed next to 
it, this is due to multiple cross-ring cleavages that lead to the same m/z value. 
SFTI-1 Reduce / Alkylate CID  SFTI-1 Orn Reduce / 
Alkylate CID 
 SFTI-1 Reduce / Alkylate UVPD  SFTI-1 Orn Reduce / 
Alkylate UVPD 
m/z Fragment  m/z Fragment  m/z Fragment  m/z Fragment 
1435.68 29|101||2|1  1490.71, 
745.86 
16|67  1435.68 29|101||2|1  1490.71, 
745.86 
16|67 
 38|2||96|101      38|2||96|101    
   1424.64, 
712.33 
73|72     1424.64, 
712.33 
73|72 
1419.66 29|101||1|35     1429.65 29|101||81|80    
 28|33||35|5  1416.67 14|13   55|11||17|16  1416.67 14|13 
 28|33||95|86      65|17||23|70    
 33|37||5|4  1387.65 62|14   77|91||86|85  1387.65 62|14 
 33|37||86|85      91|81||96|101    
   1326.69, 
262.09 
77|104     1311.61 77|91 
1383.66 2|1||43|8     1419.66 29|101||1|35    





29|101||5|4      28|33||95|86    
 38|2||95|86  1204.59, 
384.19 
49|51   33|37||5|4  1198.59, 
390.18 
81|80 
 2|1||86|85      33|37||86|85    
 1|35||85|96  1198.59, 
390.18 
81|80     1180.58 80|95 
 35|5||96|101     1391.66 28|33||5|4    
   1178.58, 
410.16 
47|49   33|37||95|86  1178.58, 
410.16 
47|49 
1259.62 28|33||43|8      1|35||96|101    
 33|37||8|7  1111.56, 
477.21 
86|85     1138.52 95|86 
      1332.62, 661.8, 
308.19 
29|101||5|4    
1162.57, 
468.22 
29|101||8|7  1070.53 7|47   38|2||95|86  1111.56, 
477.21 
86|85 
 43|8||96|101      2|1||86|85    
   1057.53, 
530.26 
8|7   1|35||85|96  1070.53 7|47 
1112.55, 
518.24 
28|33||47|49      35|5||96|101    
 33|37||49|51  1030.51, 
279.62 
43|8     1057.53, 
530.26 
8|7 
 38|2||55|11     1294.6 2|1||95|86    
 2|1||11|10  998.48, 
590.30 
29|101   35|5||49|51  998.48, 
590.30 
29|101 
 1|35||10|62      5|4||96|101    
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Table 1.1 (continued) 
   929.33, 
330.68 
28|33     914.44 4|43 
1040.5 29|101||24|23     1277.56 38|2||80|95    
 65|17||80|95  901.43 33|37     901.43 33|37 
 67|24||96|101     1259.62 28|33||43|8    
   897.49 5|4   33|37||8|7  897.49 5|4 
1015.5, 615.29 29|101||49|51          
 28|33||55|11  737.85 17|16  1209.51 35|5||95|86  804.37 2|1 
 33|37||11|10      5|4||86|85    
 47|49||96|101  719.37 35|5   4|43||85|96  737.85 17|16 
           
997.49 65|17||95|85  694.33 62|14  1162.57, 
468.22 
29|101||8|7  719.37 35|5 
 17|16||86|85      43|8||96|101    
 16|67||85|96  562.3 96|101     694.33 62|14 
      1134.57 38|2||77|104    
900.47 28|33||62|14        661.35 28|33 
 33|37||14|13     1112.55, 
518.24 
28|33||47|49    
       33|37||49|51  562.3 96|101 
827.37 29|101||14|13      38|2||55|11    
 33|37||16|67      2|1||11|10  287.14 11|10 
 1|35||67|24      1|35||10|62    
 62|14||96|101        279.62 43|8 
      1083.54 28|33||49|51    
758.86 29|101||86|85      38|2||11|10    
 38|2||35|5          
 2|1||5|4     1015.5, 615.29 29|101||49|51    
 1|35||4|43      28|33||55|11    
       33|37||11|10    
749.38 5|4||43|8      47|49||96|101    
           
740.38 38|2||23|70     987.51 28|33||11|10    
 11|10||96|101      49|51||96|101    
           
715.34 29|101||81|80     944.43 47|49||85|96    
 33|37||67|24          
 77|91||86|85     900.47 28|33||62|14    
 91|81||96|101      33|37||14|13    
           
651.29 29|101||77|104     827.37 29|101||14|13    
       33|37||16|67    
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Table 1.1 (continued) 
603.3 62|14||91|81      1|35||67|24    
 14|13||81|80      62|14||96|101    
 13|65||80|95          
      766.87 29|101||33|37    
587.3 29|101||47|49      28|33||38|2    
 33|37||55|11      33|37||2|1    
           
377.22 43|8||77|91     758.86 29|101||86|85    
       38|2||35|5    
371.17 28|33||43|8      2|1||5|4    
 33|37||8|7      1|35||4|43    
           
      740.38 38|2||23|70    
       11|10||96|101    
           
      715.34 29|101||81|80    
       33|37||67|24    
       77|91||86|85    
       91|81||96|101    
           
      682.36 7|47||81|80    
           
      603.3 62|14||91|81    
       14|13||81|80    
       13|65||80|95    
           
      587.3 29|101||47|49    
       33|37||55|11    
           
      542.27 10|62||89|104    
       23|70||96|101    
           
      530.28 7|47||67|24    
       16|67||81|80    
           
      485.26 38|2||14|13    
       65|17||86|85    
           
      440.23 29|101||43|8    
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Table 1.1 (continued) 
      377.22 43|8||77|91    
           
      371.17 28|33||43|8    














Figure 1.19. CID mass spectra (240K resolution) of doubly charged (a) unmodified 
SFTI-1 (1513.60 Da) and (b) ornithine-modified SFTI-1 (1471.60 Da). 
(NCE = 24) An asterisk (*) represents presence of the modification from 





Figure 1.20. UVPD mass spectra (2.5 mJ, 1 pulse, 240K resolution) of doubly charged 
(a) unmodified SFTI-1 (1513.60 Da) and (b) ornithine-modified SFTI-1 
(1471.60 Da). (NCE = 24) An asterisk (*) represents presence of the 
modification from arginine to ornithine. 
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Figure 1.21. Fragmentation map of unmodified SFTI-1 that has been reduced and 
alkylated. Red cleavages correspond to those fragment ions unique to CID; 
blue cleavages correspond to fragment ions unique to UVPD; green 
cleavages correspond to fragment ions produced by CID and UVPD. (note: 
not all fragment ions are displayed, please see Table 1.1 for a  full list of all 




Conversion of arginine residues to ornithine residues provided an effective way to 
promote ring opening reactions of stapled or cyclic peptides chemically rather than 
enzymatically, with greater specificity than tryptic digestion. The preferential heterolytic 
cleavage C-terminal to the ornithine residue upon activation led to an N-terminal ion that 
terminated with a sixmembered lactam ring. The ornithine effect allowed characterization 
of isomeric stapled peptides as well as the cyclic peptide SFTI-1 upon CID or UVPD. A 
custom algorithm was developed to facilitate assignment of mass values to all possible 
fragment ions created upon cleavage of two bonds, including cross-ring cleavages. Use of 
this algorithm simplified the interpretation and assignment of fragment ions produced 




Chapter Two: Energy Resolved Mass Spectrometry of Lipid A Variants 
by Multiple MS/MS Techniques 
OUTLINE 2.1 
 Lipid A molecules consist of a diglucosamine sugar backbone with a number of 
acyl chains which vary in their length and connectivity. Because of the challenging nature 
of characterizing these molecules and differentiating between isomeric species, an 
energy-resolved MS/MS strategy was undertaken to track the fragmentation trends and 
map genealogies of  product ions originating from consecutive cleavages of acyl chains. 
Ten lipid A molecules were analyzed via this energy- resolved MS
2
 approach.  
Generalizations were developed based on the number and locations of the primary and 
secondary acyl chains as well as variations in preferential cleavages arising from the 
location of the phosphate groups.   
INTRODUCTION 2.2 
Gram-negative bacteria are responsible for a variety of food-borne illnesses, 
respiratory and urinary tract infections, sexually transmitted diseases, and highly 
aggressive immune responses which can be fatal if proper treatment is unavailable [53–
56]. The outer membrane of these bacteria contains a structurally complex 
lipopolysaccharide (LPS) responsible for many of their infectious and toxic properties 
[57, 58]. LPS is structurally organized into three unique, covalently linked regions which 
extend from the surface of the bacterial membrane [59]. At the exterior is a highly 
variable polyglycan O-antigen region, connected to a non-repeating saccharide core, 
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followed by a hydrophobic domain known as lipid A, which is responsible for fastening 
LPS to the membrane surface [60, 61]. 
The sugar backbone of lipid A is highly conserved in most bacteria, comprised of 
two pyranosidic hexosamine residues as β(1,6)-linked glucosamine dimers. Branching 
from this central motif are a series of highly variable (R)-3-hydroxy acyl groups linked at 
the N-2, O-3, N-2' and O-3' positions by ester or amide bonds [62]. Owing to random 
mutations along with certain modulating environmental factors, the length and number of 
acyl chains extending from the sugar backbone of lipid A varies across bacterial species 
[63]. One or two phosphates are usually found at the 1’ and 4’ carbon positions of the 
diglucosamine backbone, occasionally with variable substituents including glycans and 
phosphoethanolamine [64]. One example of this structural variability is found in the lipid 
A of P. aeruginosa bacteria isolated from the airways of cystic fibrosis patients [65,66]. 
The lipid A found in the clinical isolates incorporated both a palmitate moiety and an 
aminoarabinose group and retained a C10 fatty acid, all specific modifications not found 
in other strains of P. aeruginosa, a finding that suggested unique adaptation of the 
bacteria in a way that may contribute to antimicrobial resistance [65,66]. Currently, our 
understanding of the structural changes of lipid A and the way in which they help impart 
antibiotic resistance and recognition failure by the immune system is limited. As a result, 
it is imperative that efficient and reliable methods be developed to improve analysis of 
this diverse structure. 
Currently, most mass spectrometry-based lipid analyses rely on MS/MS in order 
to generate fragmentation profiles for structural characterization. Collision induced 
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dissociation (CID) and high-energy collisional dissociation (HCD) have been particularly 
useful in generating fragment libraries necessary for accurate profiling of different lipid 
A variants [65–73].
 
An alternative to collision-based methods for ion 
activation/fragmentation is ultraviolet photodissociation (UVPD) [74–76]. As shown 
previously, UVPD results in structure-specific glycosidic and cross-ring fragments of 
lipid A and affords richer fragmentation patterns when compared to conventional 
collisional activation methods [77–85]. Recent work by the Goodlett group successfully 
determined the structures of various lipid A using an automated hierarchical tandem MS 
algorithm known as HitMS [86]. This profiling method interrogated diagnostic fragment 
ions and neutral losses across MSn events by aligning each fragment (based on m/z value) 
with its most probable structure. We envisioned that a combination of MS
n
 and energy-
variable MS/MS strategies, ideally coupled with powerful algorithms like HitMS, could 
further facilitate characterization of lipid A and assignment of structures.  In order to 
overcome some of the experimental and data processing obstacles encountered in current 
lipid A studies, our group recently demonstrated a hierarchical method, UVliPiD, for 
identification of acyl chain linkages in bis-phosphoryl lipid A structures [87]. Following 
fragmentation of lipid A by an initial stage of UVPD, the resulting charge-reduced 
photodetachment products were subjected to secondary activation using CID without 
isolation of specific intermediates. However, the rather naïve guesswork of this decision-
based approach spurred our interest in refining the method by incorporating specific 
predictive rules based on monitoring the fragmentation pathways as a function of energy 
deposition.  
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In recent years, energy-resolved mass spectrometry (ERMS) has proved to be a 
valuable technique for mapping complex oligosaccharides and other biopolymers based 
on trends in fragmentation relative to internal energy deposited during the activation 
event [30, 31].  Even for molecules that generate the identical sets of fragment ions upon 
MS/MS, ERMS may allow an opportunity to differentiate isomers based on variations in 
the fragmentation trends as a function of energy.  Here we use energy-variable HCD, 
CID, and UVPD to compare the preferred fragmentation pathways and map the 
genealogies of fragmentation of a series of lipid A molecules in an effort to develop rules 
for predicting lipid A fragmentation patterns and to facilitate development of fragment 
ion assignment algorithms. HCD proved to be particularly useful for tracking secondary 
or consecutive fragmentation routes. Further, changes in phosphorylation appeared to 
cause predictable variations in specific dissociation events.   
EXPERIMENTAL 2.3 
Synthetic monophosphoryl lipid A (MPLA), synthetic monophosphoryl 3-deacyl 
lipid A (MP3DALA), and detoxified monophosphoryl lipid A (DMPLA) from 
Salmonella minnesota R595 were purchased from Avanti Polar Lipids (Alabaster, AL) 
and used without further purification. E. coli bis-phosphorylated lipid A was purchased 
from Sigma-Aldrich (St. Louis, MO) and also used without further purification. 
Additionally, lipid A variants were isolated and purified from E. coli expressing LpxJ 
from C. jejuni, from Acinetobacter baumannii, from W. succinogenes, and from E. coli 
strain BN2, as described previously [83, 90, 91]. HPLC grade chloroform, methanol, and 
water used during sample preparation were purchased from EMD Millipore (Billerica, 
 41 
MA). Manual determination of fragment ions was accomplished using the ChemDraw 
software suite (Perkin Elmer, Waltham, MA). 
All lipid A samples used in this study were dissolved in 74:23:3 
chloroform:methanol:water with final concentrations of 10 µM followed by analysis 
using both a Thermo Scientific Velos Pro dual linear ion trap and a Thermo Scientific 
Orbitrap Fusion mass spectrometer (San Jose, CA). Both mass spectrometers were 
equipped with a 193 nm excimer laser (Coherent, Santa Clara, CA) to perform 
photodissociation, as previously described [77, 92]. Static emitters were used to transport 
lipid A molecules into the gas phase via a 1.5 mm o.d. glass capillary pulled to a tip of 
less than 1 µm by a Sutter Instrument P2000 laser puller (Novato, CA). Solutions of the 
lipid A molecules were loaded into the pulled glass capillary and a platinum wire was 
inserted, generating ions when a potential of 1000-1500 V was applied to the wire. All 
experiments were conducted in the negative ion mode on the mass spectrometer, and 
CID, HCD, and UVPD were manually stepped to generate ERMS plots for the MS2 
spectra. CID and HCD were stepped from NCE 0-50 in increments of 5 NCE, and UVPD 
was stepped in both energy (0-4 mJ, in 0.5 mJ increments) and pulses (1-11 pulses, in 2 
pulse increments). For high resolution data collection on the Orbitrap Fusion mass 
spectrometer, a resolution of 120 K was used and a signal-to-noise threshold of 3 was 
used in analyzing the deconvoluted data in Xtract.  
RESULTS AND DISCUSSION 2.4 
ESI of lipid A species resulted in production of singly or doubly deprotonated 
species depending on whether the lipid A possessed one or two phosphate groups.  HCD 
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and UVPD were used to characterize the deprotonated species in an energy variable 
manner to obtain information about the dominant fragmentation pathways and their 
genealogies as a function of energy deposition. ERMS plots were generated via variation 
of the collision energy for HCD or the number of laser pulses for UVPD. The ERMS 
plots give insight into the variations in fragment ion distributions as a function of energy 
deposition, thus providing a convenient way to track the conversion of primary fragment 
ions into secondary fragment ions and reveal the relative labilities of the acyl chains and 
the sequential order in which they are lost. For the results shown, fragmentation 
nomenclature from Domon et al. [93] and Morrison et al. [87] is adopted. All lipid A 
variants used in this study are shown in Figure 2.1 and listed with their neutral masses 
and abbreviations used henceforth. 
 
Figure 2.1. Supplementary Figure S1: All 10 lipid A variants evaluated. (a) 
monophosphoryl lipid A (1745.28 Da, lAA); (b) detoxified lipid A (1717.25 
Da, lAB); (c) monophosphoryl 3-deacyl lipid A (1519.09 Da, lAC); (d) E. 
coli strain BN2E (1507.05 Da, lAD); (e) E. coli strain BN2F (1507.05 Da, 
lAE); (f) Acinetobacter baumannii expressing lpxL (1713.13 Da, lAF); (g) 
bisphosphorylated lipid A (1797.22 Da; lAG); (h) W. succinogenes lpxJ 
(1587.02 Da, lAH); (i) C. jejuni 240 0482 (1643.08 Da, lAI); (j) C. jejuni 
lpxJ (1643.08 Da, lAJ)  
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Figure 2.2. (a) Structure of monophosphoryl lipid A (monoisotopic mass 1745.3 Da) and 
the corresponding MS/MS spectra of the deprotonated lipid by: (b) CID at 
NCE 35, (c) HCD at NCE 25, and (d) UVPD at 2.5 mJ for seven pulses. 
Only the most prominent fragment ions are labelled.   ERMS plots are 
shown in (e) HCD and f) UVPD.   
As a representative example, lAA was analyzed via CID, HCD, and UVPD in an 
energy-variable method. The phosphate moiety is located on the non-reducing 
glucosamine, and this lipid A contains four primary acyl chains (at the 3’, 2’, 3, and 2 
positions) as well as two secondary acyl chains of equal length located at the 3’- and 2’- 
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positions (Figure 2.2a). The corresponding CID, HCD, and UVPD spectra are shown in 
Figure 2.2b, 2.2c, and 2.2d, respectively, and the companion energy-variable curves are 
shown in Figure 2.3 (CID), 2.2e (HCD), and 2.2f (UVPD).  The most dominant fragment 
ions identified resulted from losses of primary and secondary acyl chains at the 3’α, 3’ε, 
3α, and 3’β positions (all of which are labelled on the structure in Figure 2.2a). There 
was also one cross-ring cleavage (
2,4
A2) that occurred on the unphosphorylated 
glucosamine. The MS/MS spectra revealed that the various acyl chains were cleaved 
individually (cleavage at 3’ε, 3α or 3’α) or as paired combinations (cleavage at 3’ε with 
3α; or loss of 3α with 3’α or 3’ or 3’ε; or loss of 3’α with 3 or with cross-ring cleavage 
2,4
A2).  For HCD, the 3’ε and 3α cleavages were observed at the lowest onset energies. As 
the HCD energy was increased, the primary fragments originating from these cleavages 
were depleted, and new secondary fragment ions appeared, including ones attributed to 
cleavages of 3’ε + 3α and 3’α + 3α.   The cleavage of the 3’α chain appeared at 20 NCE, 
along with secondary products due to sequential cleavages: 3’α + 3 and 3’α + 
2,4
A2.   
Interestingly, the 2’ and 2 acyl chains were never cleaved individually nor in tandem with 
any other acyl chain.  Closer inspection of the energy-variable HCD and UVPD curves in 
Figure 2.2e and 2.2f illustrates that the onsets for sequential fragmentation pathways 
were well-demarcated for HCD, whereas the onsets were identical for virtually all of the 
fragmentation pathways upon UVPD, including both cleavages of individual acyl chains 
and pairs of acyl chains.  This behavior reflects the high internal energy deposition upon 
absorption of one or more UV photons and ultimately provides little genealogical 
information about fragmentation of lipid A.  This type of energy-variable UVPD plot is 
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consistent for other lipid A, and thus the remainder of the study will focus on the energy-
variable HCD curves which more clearly illustrate the step-wise nature of lipid A 
fragmentation. In direct comparison to the results obtained from the energy-variable 
analysis of lAA, the fragmentation preferences via HCD for lAB are shown schematically 
in Figure 2.4. Similarly to lAA, lAB (which has the same acyl chain connectivity, the 
only difference being the length of the 2’ε chain) demonstrates initial losses of the 3’ε 
and 3α acyl chains, followed by loss of the 3’α acyl chain and combinations of losses at 
3’ε + 3α, 3’β + 3α, 3’α + 3α, and 3’α + 
2,4
A2. The corresponding energy variable HCD 
and UVPD plots for lAB is shown in Figure 2.5 and Figure 2.6. 
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Figure 2.3. (a) CID ERMS of lAA and (b) the structure. CID ERMS does not afford the 
same genealogical information that HCD and UVPD do.  
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Figure 2.5. lAB MS2 spectra using HCD at NCE=25 (a) and the corresponding HCD 
ERMS plot (b). The structure of lAB is shown in (c). 
 49 
 
Figure 2.6. lAB MS2 spectra using UVPD at 3mJ, 5 pulses (a) and the corresponding 
UVPD ERMS plot (b). The structure for lAB is shown in (c). 
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Energy variable HCD was used to examine the impact of the acyl chains on the 
preferential cleavages at different positions.  The resulting plots are shown for three 
monophosphoryl lipid A in Figure 2.7 (as well as lAA in Figure 2.2 and lAB in Figure 
2.5), with the identified acyl chain and cross-ring cleavages mapped on each structure.  
The lipids in Figure 2.7 all have five acyl chains; two are isomers.  All five mono-
phosphorylated lipid A included in this have a secondary acyl chain at the N-2’ position; 
both lAA and lAB have an additional secondary acyl chain at the O-3’ position. Upon 
comparison of the ERMS curves, it is clear that the presence of secondary acyl chains 
significantly modulates the fragmentation patterns owing to their lability upon activation 
of lipid A.  Cleavage of the secondary acyl chain at the O-3’ position (3’) is particularly 
favored, thus representing a dominant fragmentation observed at the lowest HCD 
energies. Loss of the O-3’ secondary chain may occur in conjunction with cleavages of 
other acyl chains at higher collision energies, as evidenced by the trends for loss of 3’ε + 
3α for lAC, lAA, and lAB. For lAD and lAE which lack the 3’ secondary chain, cleavage 
of the secondary acyl chain at the 2’ position (2’)  is preferred. For all of the 
monophosphoryl lipid A, cleavages of the 3’ and 3 acyl chains are prominent, either 
alone at the lower collision energies or in conjunction with additional acyl chain 
cleavages at higher collision energies.  The higher energy onset of the combined loss of 
the acyl chains at the 3’ and 3 positions suggests that loss of the 3’ chain occurs first, 
followed by the acyl chain at the 3 position. In contrast to the trends observed for lAA for 
which there was an abundant ion attributed to cleavage of the 3’ε and 3α positions 
simultaneously (Figure 2.2e), this pathway is not highly favored for lAC and instead 
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cleavage of the 3’ chain (3’ε) in conjunction with cross-ring cleavage of the reducing end 
sugar (
2,4
A2) is favored (Figure 2.7d). This observation is particularly useful for 
structural elucidation of the acyl chain positions of lipid A. While the secondary 3’ chain 
was not present for the other two monophosphoryl lipid A structures, lAD and lAE, they 
still exhibited combinatorial losses of acyl chains as a function of increasing collisional 
energy. lAD favored initial cleavage at the 3’α position, whereas lAE favored cleavage at 
the 2’ε position. Both of these monophosphoryl lipid A isomers exhibited similar 2’ε and 
3’α cleavages in conjunction with the acyl chain at the 3-position (α and β cleavages) 
(Figure 2.7e, f). The raw HCD spectrum for lAC at NCE=20 is shown in Figure 2.8.  
 
Figure 2.7. lAC, lAD, and lAE structures with key cleavage sites indicated (a, b, c) and 




Figure 2.8. MS2 HCD spectra of lAC at NCE=20. The structure of lAC is shown in (b). 
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The fragmentation behavior of two isomeric lipid A, lAD and lAE, were analyzed 
in greater detail to evaluate the impact of the position of the phosphate group.  For lAD, 
the phosphate moiety is located on the non-reducing sugar, whereas for lAE the 
phosphate moiety is located on the reducing sugar. Phosphorylation configurations have 
been deciphered previously  for lipid A molecules from Yersinia pestis using MS
n
 
methods [73]. HCD and MS
3
 spectra for deprotonated lAD and lAE are shown in Figure 
2.9. The first stage of HCD results in similar products for the two lipids (dominant 
cleavage at the 3’α and 2’ε positions), with lAD favoring the 3’α cleavage and lAE 
favoring the 2’ε cleavage (Figure 2.9a, b). Each of these primary products was isolated 
and subjected to a second stage of HCD, resulting in the MS
3
 spectra shown in Figures 
2.9c-f.  Isolation and activation of the dominant 3’α cleavage product for lAD resulted in 
subsequent cleavage of the O-3 acyl chain (3α or 3β cleavage) or cross ring cleavage of 
the reducing sugar (
0,4
A2) (Figure 2.9c). In contrast, isolation and activation of the 3’α 
cleavage product for lAE results in cleavage of the O-3 acyl chain (3α loss) or 
elimination of the secondary 2’ acyl chain (2’ε), the latter not observed for the lAD 
isomer  (Figure 2.9d). The striking differences in the MS
3
 spectra in Figure 2.9c, d 
highlight the impact of the location of the phosphate group on the consecutive cleavages 
of acyl chains. Isolation and activation of the 2’ε cleavage products for both lAD and lAE 
leads to production of two prominent secondary fragment ions via sequential losses of 
both the 3 and 3’ acyl chains (3 and 3’ cleavages in Figure 2.9e, f).  The order in 




Figure 2.9. HCD spectra of deprotonated (a) lAD and (b) lAE. MS
3
 spectra in (c) to (f) 
reveal the sequential order of 3’α and 2’ε chain cleavage. 
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Five additional lipid A molecules were analyzed via energy-variable HCD to 
probe the impact of the number and positions of acyl chains for bis-phosphorylated lipids.  
Both lAF and lAG have six acyl chains (Figure 2.10), the only difference being the 
location of the secondary acyl chains. lAF has secondary acyl chains located at the 3’- 
and 2-positions (Figure 2.10a), whereas lAG has secondary acyl chains located at the 3’- 
and 2’-positions (Figure 2.10b). The dominant lowest energy fragmentation pathway for 
both lipids entails cleavage of the secondary acyl chain at the 3’ position (3’ε). Sequential 
fragmentation results in cleavage of two or even three acyl chains at the 3’- and 3-
positions. In fact, for these two lipids, eight of the dominant fragmentation pathways are 
identical. Interestingly, lAF demonstrates a loss of two secondary acyl chains (Figure 
2.10c, 3’β + 3β + 2PO3 product), whereas lAG never exhibits the loss of two 
secondary acyl chains (Figure 2.10d), leading to the conclusion that a secondary acyl 
chain at the 2-position (2) is more labile than one at the 2’-position (2’).  
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Figure 2.10. Structures of (a) lAF and (b) lAG. The HCD ERMS plots are shown for 
each doubly deprotonated lipid in (c) and (d), respectively. 
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Figure 2.11. MS2 HCD spectra of (a) lAF and (b) lAG  at NCE=30 and their structures 
(c) and (d), respectively. 
Three other bisphosphorylated lipid A species were subjected to energy-resolved 
MS/MS experiments. Of the three species examined, lAH (Figure 2.12a) and lAI 
(Figure 2.12b) have a secondary acyl chain at the 3’-position, whereas lAJ (Figure 
2.12c) has a secondary acyl chain at the 2-position. All three lipids displayed a loss of the 
secondary acyl chain, whether at the 3’- or 2-position, as the most dominant 
fragmentation pathway (Figure 2.12d-f, 3’ or 2). The HCD spectra and energy-
resolved trends for lAH and lAI are nearly identical, an expected outcome for these two 
analogs that differ only in the length of the secondary acyl chain at the 3’ position.  
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Interestingly, simple loss of the phosphate moiety seems to be a more favored process 
when the secondary acyl chain is located at the 2-position (in the case of lAJ, Figure 
2.12f) than when the secondary acyl chain is located at the 3’-position (Figure 2.12d,e).  
Interestingly, the loss of phosphate alone is only prominent for lAJ, the only lipid A with 
a secondary acyl chain  at the 2-position and no other secondary chains. HCD spectra for 
lAH, lAI, and lAJ can be found in Figure 2.13, Figure 2.14, and Figure 2.15, 
respectively.   
 
Figure 2.12. lAH, lAI, and lAJ structures with key cleavage sites indicated (a, b, c) and 
respective HCD ERMS plots (d, e, f) for the deprotonated lipids. 
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Figure 2.15. lAJ MS2 spectra using HCD at NCE=25 (a). The structure of lAJ is shown 
in (b). 
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Several correlations are evident that show the impact of the number of phosphate 
moieties of lipid A on the fragmentation behavior. In the case of mono-phosphate lAA, 
the dominant primary and secondary fragment ions observed originated from cleavage of 
an acyl chain or a cross-ring cleavage occurring (Figure 2.2).   Analog bis-phosphate 
lAG shows many of these same characteristics, but competing processes related to 
phosphate losses are common (Figure 2.10d). Phosphate loss from lAA renders the 
resulting ions non-detectable in the negative mode.  Comparison of lAF and lAH shows 
the influence of the number of secondary chains on the fragmentation patterns. lAF has 
two secondary acyl chains present, at the 3’- and 2-positions, where lAH has only has a 
single secondary acyl chain located at the 3’-position. Both molecules favor the 3’ε 
cleavage, but lAH (Figure 2.12d) undergoes phosphate loss more readily than lAF 
molecule (Figure 2.10c). Comparison of lAF to lAJ, lAF demonstrates that the presence 
of two secondary acyl chain (3’- and 2-positions) facilitates the loss of the phosphate 
group.  The role of a secondary acyl chain located at the 2-position can be evaluated by 
comparing the fragmentation of lAF to lAH. lAF  displays loss of both secondary chains, 
thus demonstrating the lability of the secondary chains relative to the primary chains.   
CONCLUSIONS 2.5 
Energy resolved mass spectrometry of lipid A molecules enables detailed 
characterization of the fragmentation patterns via the genealogical patterns as specific 
chains are cleaved.   HCD yields the most comprehensive information about the 
combinatorial cleavage of acyl chains and the preferential cleavage of the chains.  
Cleavage of a 3’ secondary chain is most favorable, followed by cleavages of primary 
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acyl chains at the 3 and 3’ position. For bisphosphorylated lipid A species, loss of a 
phosphate moiety occurs in conjunction with dominant secondary and primary acyl chain 
fragmentation. In some instances, cross ring cleavages of the reducing sugar are 
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